The Experts below are selected from a list of 426 Experts worldwide ranked by ideXlab platform
Felix S Chew - One of the best experts on this subject based on the ideXlab platform.
-
chronic recurrent multifocal osteomyelitis review
American Journal of Roentgenology, 2011Co-Authors: Ramesh S Iyer, Mahesh M Thapa, Felix S ChewAbstract:Objective Chronic recurrent multifocal osteomyelitis (CRMO) is primarily a disorder of children and adolescents characterized by episodic osseous pain over several years. The objective of this article is to present an overview of this entity with an emphasis on imaging manifestations. Conclusion CRMO can be a difficult diagnosis, often with nonspecific imaging findings. The critical factors leading to its diagnosis are patient demographics, clinical course, and distribution. However, a greater understanding of the imaging appearance during both active and reparative phases may lead to improved detection. Introduction Chronic recurrent multifocal osteomyelitis (CRMO) is a skeletal disorder of unknown cause, occurring primarily in children and adolescents. The entity was first described by Giedion et al. [1] in 1972 as "an unusual form of multifocal bone lesions with subacute and chronic symmetrical osteomyelitis." Later, Bjorksten and Boquist [2] noted its association with Pustulosis palmoplantaris and developed the term "chronic recurrent multifocal osteomyelitis." Between 200 and 300 cases of CRMO have been reported in the literature worldwide, consisting mainly of case series with relatively brief follow-up durations [3]. However, because of increasing disease awareness and longer clinical observation periods, this disorder is likely more common than previously realized. CRMO is a diagnosis of exclusion based on the following criteria: lack of causative organism; no abscess formation, fistula, or sequestra; atypical location compared with infectious osteomyelitis, with frequent involvement of the clavicle and often showing multifocality; radiographic appearance of subacute or chronic osteomyelitis; nonspecific histopathologic and laboratory findings compatible with subacute or chronic osteomyelitis; characteristic prolonged, fluctuating course with recurrent episodic pain over several years; and accompanying Pustulosis palmoplantaris or acne [2, 4]. Clinical Findings CRMO is characterized by the insidious onset of pain and swelling corresponding to the involved bones [5, 6]. Most cases (up to 85%) occur in females, with a median age of onset of 10 years [7, 8]. The disease course is typically prolonged over several years. punctuated by periodic exacerbations. Symptoms may either recur at sites affected previously or involve new areas with subsequent flare-ups. Patients may experience concomitant systemic symptoms including low-grade fevers and generalized malaise [9]. CRMO may be accompanied by many skin disorders, most commonly Pustulosis palmoplantaris, that may recur along with the osseous exacerbations [2, 5, 10]. The lesions are predominantly situated in the metaphyses of tubular bones, followed by the clavicle and spine [2, 6, 11-13]. Within tubular bones there is a predilection for the lower extremities, with the distal femur, proximal tibia, distal tibia, and distal fibula most commonly affected [14]. The disease may less frequently involve the ribs [10, 12, 15-17], sternum [15], and pelvis [18]. Symmetric involvement is common [14], and multifocality is virtually always present. The clinical course of CRMO may last anywhere from 7 to 25 years [3, 11, 19]. Treatment generally involves antiinflammatory agents targeting symptomatic relief, particularly nonsteroidal antiinflammatory drugs (NSAIDs) [20]. NSAIDs are usually effective in symptomatic relief, with response rates of up to 80% [7, 21].
Menno A. De Rie - One of the best experts on this subject based on the ideXlab platform.
-
Psoriasiform Eruption and Worsening of Pustulosis palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab
Dermatology and therapy, 2016Co-Authors: Nathalie A. Bogaards, Menno A. De RieAbstract:Introduction Tumor necrosis factor (TNF)-α inhibitors are widely used for the treatment of inflammatory diseases. One of the side effects of TNF-inhibitors is the development of a psoriatiform eruption, also known as paradoxical psoriasis. In this case report, we describe a patient with this side effect after treatment with adalimumab and etanercept.
H Sonozaki - One of the best experts on this subject based on the ideXlab platform.
-
Palmoplantar pustulotic arthro-osteitis of the peripheral joints with no sternocostoclavicular lesions.
Annals of the rheumatic diseases, 1992Co-Authors: M Takagi, J Oda, N Tsuzuki, H SonozakiAbstract:A 45 year old woman presented with swelling and pain on joint movement of her knees, although joint movement was relatively well maintained. Five years previously the patient had been diagnosed as having Pustulosis palmoplantaris by a dermatologist. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) had no effect, but treatment with 5 mg/day prednisolone caused remission of both the joint pain and swelling and the Pustulosis palmoplantaris. There were no sternocostoclavicular lesions at any time during treatment. Clinical findings in this patient were different from previous reports and she was diagnosed as having palmoplantar pustulotic arthro-osteitis affecting the peripheral joints.
A Leiská - One of the best experts on this subject based on the ideXlab platform.
-
The SAPHO syndrome.
Acta dermato-venereologica, 1993Co-Authors: O Vohradníková, F Záruba, S Polásková, J Hoza, A LeiskáAbstract:We report two cases of the SAPHO syndrome (synovitis, acne conglobata, Pustulosis palmoplantaris, hyperostosis and osteitis). This syndrome has been published in the pediatric and rheumatological literature in recent years.
Ramesh S Iyer - One of the best experts on this subject based on the ideXlab platform.
-
chronic recurrent multifocal osteomyelitis review
American Journal of Roentgenology, 2011Co-Authors: Ramesh S Iyer, Mahesh M Thapa, Felix S ChewAbstract:Objective Chronic recurrent multifocal osteomyelitis (CRMO) is primarily a disorder of children and adolescents characterized by episodic osseous pain over several years. The objective of this article is to present an overview of this entity with an emphasis on imaging manifestations. Conclusion CRMO can be a difficult diagnosis, often with nonspecific imaging findings. The critical factors leading to its diagnosis are patient demographics, clinical course, and distribution. However, a greater understanding of the imaging appearance during both active and reparative phases may lead to improved detection. Introduction Chronic recurrent multifocal osteomyelitis (CRMO) is a skeletal disorder of unknown cause, occurring primarily in children and adolescents. The entity was first described by Giedion et al. [1] in 1972 as "an unusual form of multifocal bone lesions with subacute and chronic symmetrical osteomyelitis." Later, Bjorksten and Boquist [2] noted its association with Pustulosis palmoplantaris and developed the term "chronic recurrent multifocal osteomyelitis." Between 200 and 300 cases of CRMO have been reported in the literature worldwide, consisting mainly of case series with relatively brief follow-up durations [3]. However, because of increasing disease awareness and longer clinical observation periods, this disorder is likely more common than previously realized. CRMO is a diagnosis of exclusion based on the following criteria: lack of causative organism; no abscess formation, fistula, or sequestra; atypical location compared with infectious osteomyelitis, with frequent involvement of the clavicle and often showing multifocality; radiographic appearance of subacute or chronic osteomyelitis; nonspecific histopathologic and laboratory findings compatible with subacute or chronic osteomyelitis; characteristic prolonged, fluctuating course with recurrent episodic pain over several years; and accompanying Pustulosis palmoplantaris or acne [2, 4]. Clinical Findings CRMO is characterized by the insidious onset of pain and swelling corresponding to the involved bones [5, 6]. Most cases (up to 85%) occur in females, with a median age of onset of 10 years [7, 8]. The disease course is typically prolonged over several years. punctuated by periodic exacerbations. Symptoms may either recur at sites affected previously or involve new areas with subsequent flare-ups. Patients may experience concomitant systemic symptoms including low-grade fevers and generalized malaise [9]. CRMO may be accompanied by many skin disorders, most commonly Pustulosis palmoplantaris, that may recur along with the osseous exacerbations [2, 5, 10]. The lesions are predominantly situated in the metaphyses of tubular bones, followed by the clavicle and spine [2, 6, 11-13]. Within tubular bones there is a predilection for the lower extremities, with the distal femur, proximal tibia, distal tibia, and distal fibula most commonly affected [14]. The disease may less frequently involve the ribs [10, 12, 15-17], sternum [15], and pelvis [18]. Symmetric involvement is common [14], and multifocality is virtually always present. The clinical course of CRMO may last anywhere from 7 to 25 years [3, 11, 19]. Treatment generally involves antiinflammatory agents targeting symptomatic relief, particularly nonsteroidal antiinflammatory drugs (NSAIDs) [20]. NSAIDs are usually effective in symptomatic relief, with response rates of up to 80% [7, 21].
